Researchers from Uppsala University and Tomsk Polytechnic University (TPU) have detailed the discovery and preclinical evaluation of [177Lu]BQ-7876, a novel prostate-specific membrane antigen (PSMA)-targeting therapeutic for the treatment of prostate cancer.
Researchers from University Hospital Basel and Universitätsklinikum Ulm presented the discovery of novel radiotheragnostic candidates targeting C-X-C chemokine receptor 4 (CXCR4), which is highly expressed in various cancers and has been linked to poor prognosis.
Researchers from Huazhong University of Science and Technology presented the discovery and preclinical evaluation of a novel peptide PET tracer targeting LAG-3, [68Ga]NOTA-XH05, being developed as a candidate for evaluating the efficacy of cancer immunotherapy.
The discovery of new 68Ga-labeled CD38-targeted peptides for PET imaging was recently discussed by researchers from Peking University First Hospital and China National Center For Nanoscience & Technology.
Transforming growth factor β1 (TGF-β1) is a key mediator of the fibrotic response, and its dysregulation drives the formation of the fibrotic niche, which impairs the capacity of tissue repair, regeneration and homeostasis.
Researchers from Peking University Cancer Hospital presented the discovery and preclinical evaluation of [124I]IMMU-132, a trophoblast cell surface antigen 2 (Trop2)-targeting molecular probe for micro-PET imaging.
Integrin alphavbeta3 and aminopeptidase N (CD13) are important biomarkers involved in tumor angiogenesis, tumor growth and metastasis. Peptides RGD (Arg-Gly-Asp) and NGR (Asn-Gly-Arg) are the most studied peptides for targeting integrin alphavbeta3 and CD13, respectively.
Ephrin type-A receptor 2 (EphA2) is a type I transmembrane glycoprotein highly expressed in a wide range of tumors such as bladder, pancreatic, esophageal, colorectal, or non-small-cell lung cancer, among others. Furthermore, in most normal tissues, EphA2 is found at low levels and plays a relevant role in carcinogenesis control and tumor progression modulation.
Bicycle radionuclide conjugates (BRCs) have been developed as a unique radiotheranostic modality for imaging and targeting of proteins overexpressed by tumors, and they possess favorable drug-like properties allowing for effective delivery of radioisotopes. Researchers from Bicycletx Ltd. recently presented a new BRC that targets ephrin type-A receptor 2 (EphA2), named BCY-18469.